Pluri Inc. (PLUR)
IL — Healthcare Sector
Automate Your Wheel Strategy on PLUR
With Tiblio's Option Bot, you can configure your own wheel strategy including PLUR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PLUR
- Rev/Share 0.0158
- Book/Share -0.4756
- PB -70.1144
- Debt/Equity -1.3945
- CurrentRatio 0.0
- ROIC 4.4109
- MktCap 37434345.0
- FreeCF/Share -0.2775
- PFCF -2.0551
- PE -15.0077
- Debt/Assets 0.0
- DivYield 0
- ROE 4.7266
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.
PLUR
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
Acquisition of approximately 71% stake in Kokomodo Ltd. Acquisition uniquely combines Pluri's mass-scale cell production expertise with Kokomodo Ltd.
Read More
Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution
PLUR
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Food Industry Leader Teams With Ever After Foods to Accelerate Cultivated Meat Market Development Food Industry Leader Teams With Ever After Foods to Accelerate Cultivated Meat Market Development
Read More
About Pluri Inc. (PLUR)
- IPO Date 2003-06-30
- Website https://pluri-biotech.com/
- Industry Biotechnology
- CEO Mr. Yaacov Yanay
- Employees 106
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.